Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATRA 
Atara Biotherapeutics Inc (ATRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: ATRA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.33
1 Year Target Price $16.33
| 4 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.87% | Avg. Invested days 53 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 98.64M USD | Price to earnings Ratio 19.51 | 1Y Target Price 16.33 |
Price to earnings Ratio 19.51 | 1Y Target Price 16.33 | ||
Volume (30-day avg) 5 | Beta 0.26 | 52 Weeks Range 5.00 - 18.70 | Updated Date 10/31/2025 |
52 Weeks Range 5.00 - 18.70 | Updated Date 10/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.72 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.07% | Operating Margin (TTM) 26.86% |
Management Effectiveness
Return on Assets (TTM) 15.71% | Return on Equity (TTM) -2014.86% |
Valuation
Trailing PE 19.51 | Forward PE 3.63 | Enterprise Value 97038503 | Price to Sales(TTM) 0.52 |
Enterprise Value 97038503 | Price to Sales(TTM) 0.52 | ||
Enterprise Value to Revenue 0.51 | Enterprise Value to EBITDA 6.78 | Shares Outstanding 7023032 | Shares Floating 4421982 |
Shares Outstanding 7023032 | Shares Floating 4421982 | ||
Percent Insiders 21.19 | Percent Institutions 45.76 |
Upturn AI SWOT
Atara Biotherapeutics Inc
Company Overview
History and Background
Atara Biotherapeutics Inc. was founded in 2012. It focuses on developing allogeneic T-cell immunotherapies for cancer, autoimmune, and viral diseases. Key milestones include clinical trial advancements and partnerships.
Core Business Areas
- Allogeneic T-Cell Immunotherapies: Development and commercialization of allogeneic T-cell immunotherapies, using T-cells from healthy donors to target specific diseases.
Leadership and Structure
Pascal Touchon is the CEO. The organizational structure includes research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Tab-cel (tabelecleucel): Tab-cel is an allogeneic T-cell immunotherapy targeting Epstein-Barr virus (EBV)-positive cancers. While not having definitive market share information, it addresses post-transplant lymphoproliferative disease (PTLD). Competitors include conventional chemotherapy and other targeted therapies such as rituximab for PTLD.
- ATA188: ATA188 is an allogeneic T-cell immunotherapy being developed for progressive multiple sclerosis (MS). It's still in clinical trials. Competitors include existing MS therapies from companies such as Biogen (BIIB) and Novartis (NVS).
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, driven by advancements in cell and gene therapies. Competition is intense, with many companies developing novel treatments for cancer and autoimmune diseases.
Positioning
Atara is focused on allogeneic T-cell immunotherapies, offering a potentially off-the-shelf solution. Its competitive advantage lies in its allogeneic platform and specific disease targets.
Total Addressable Market (TAM)
The total addressable market for cell therapies is projected to reach billions of dollars. Atara is positioned to capture a share of this market through its pipeline of immunotherapies, particularly in EBV-associated diseases and MS.
Upturn SWOT Analysis
Strengths
- Allogeneic T-cell platform
- Targeting unmet medical needs
- Clinical trial progress
- Experienced leadership team
Weaknesses
- High cash burn rate
- Reliance on clinical trial success
- Commercialization challenges
- Regulatory hurdles
Opportunities
- Expansion into new disease targets
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Regulatory approvals
Threats
- Competition from other immunotherapy companies
- Clinical trial failures
- Regulatory delays
- Funding challenges
Competitors and Market Share
Key Competitors
- BIIB
- NVS
- GILD
- MRNA
Competitive Landscape
Atara's allogeneic approach offers potential advantages over autologous therapies, but it faces competition from established companies with approved therapies in similar indications.
Growth Trajectory and Initiatives
Historical Growth: Atara's growth has been primarily driven by clinical trial advancements and partnerships.
Future Projections: Future growth depends on clinical trial success, regulatory approvals, and commercialization of its therapies. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing clinical trials for Tab-cel and ATA188, and strategic partnerships.
Summary
Atara Biotherapeutics is a clinical-stage biopharmaceutical company focused on allogeneic T-cell immunotherapies. Its key product, Tab-cel, targets EBV-positive cancers and represents a significant opportunity. However, Atara faces challenges related to clinical trial success, regulatory approvals, and commercialization. Funding and competition remain significant risks, requiring a well-executed strategy for future growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Databases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Investment decisions should be made based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Atara Biotherapeutics Inc
Exchange NASDAQ | Headquaters Thousand Oaks, CA, United States | ||
IPO Launch date 2014-10-16 | President, CEO & Director Dr. Anhco Nguyen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.atarabio.com |
Full time employees 38 | Website https://www.atarabio.com | ||
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.